← Back to Search

Anti-metabolites

IXO regimen for Colorectal Cancer (IXOr Trial)

Phase 2
Waitlist Available
Led By Derek Jonker, MD
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up q6 months first 2 years and annually thereafter
Awards & highlights

IXOr Trial Summary

This is a prospective open label single-arm, single-institution phase II clinical trial to test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) followed by chemoradiotherapy and resection in patients with resectable non-metastatic primary rectal cancer of stage cT3-T4 N0-N2.

Eligible Conditions
  • Colorectal Cancer

IXOr Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~q6 months first 2 years and annually thereafter
This trial's timeline: 3 weeks for screening, Varies for treatment, and q6 months first 2 years and annually thereafter for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pathological complete response (pCR)
Secondary outcome measures
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
OS
Objective Response
+5 more

IXOr Trial Design

1Treatment groups
Experimental Treatment
Group I: IXO regimenExperimental Treatment1 Intervention
single-group

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,676 Total Patients Enrolled
Ottawa Regional Cancer FoundationUNKNOWN
1 Previous Clinical Trials
23 Total Patients Enrolled
SanofiIndustry Sponsor
2,164 Previous Clinical Trials
3,514,965 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer
2010. "IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01237665.
All > Rectal Cancer
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top